RegeneRx Biopharmaceuticals Inc logo

RGRX - RegeneRx Biopharmaceuticals Inc News Story

$0.21 0.0  8.0%

Last Trade - 19/04/21

Sector
Healthcare
Size
Micro Cap
Market Cap £18.7m
Enterprise Value £19.1m
Revenue £55.5k
Position in Universe 6016th / 6847

BRIEF-RegeneRx Joint Venture Enrolls Last Subject In Phase 3 Dry Eye Trial

Wed 28th October, 2020 12:31pm
Oct 28 (Reuters) - RegeneRx Biopharmaceuticals Inc
 RGRX.PK :
    * REGENERX JOINT VENTURE ENROLLS LAST SUBJECT IN PHASE 3 DRY
EYE
TRIAL

Source text for Eikon:  ID:nPnb0Kp0Xa 
Further company coverage:  RGRX.PK 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.